Last updated on March 2018

Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)

Brief description of study

The purpose of this study is to compare the clinical efficacy and safety of IAC regimen and IA regimen as induction chemotherapy for initial diagnosed AML patients. 840 cases are supposed to recruited in 3 years.

Clinical Study Identifier: NCT02323022

Contact Investigators or Research Sites near you

Start Over

Jia Chen, M.D.

The First Affiliated Hospital of Soochow University
Suzhou, China
  Connect »